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Abstract: Mild cognitive impairment (MCI) is deﬁ  ned as a condition characterized by newly 
acquired cognitive decline to an extent that is beyond that expected for age or educational back-
ground, yet not causing signiﬁ  cant functional impairment. The concept of MCI has received 
considerable attention in the literature over the past few years, and aspects related to its deﬁ  ni-
tion, prevalence, and evolution have been extensively studied and reviewed.
Here we attempt to synthesize the implications of the current status of this entity, focusing on 
the conceptual, methodological, and, in particular, the social and ethical aspects of MCI which 
have attracted less attention. We discuss the weaknesses of the concept of MCI, which is het-
erogeneous in etiology, manifestations, and outcomes, and suggest that the emergence of the 
syndrome at this stage reﬂ  ects industrial interests related to possible development of drugs for this 
disorder. On the other hand, the formal diagnosis of MCI, with its implications that the person 
may develop dementia, may have a grave impact on the psychological state of the individual, 
at a stage when prediction of outcome is tenuous and possibilities of useful interventions are 
meager. We present suggestions for the direction of future research in these areas.
Keywords: mild cognitive impairment, assessment issues, ethical issues, social issues, 
dementia
Introduction
Scientiﬁ  c and clinical research in the area of Alzheimer’s disease (AD) during the 
last years shifted their focus to early diagnosis and especially to the transitional phase 
between normal aging and dementia. Mild cognitive impairment (MCI) is presently 
used to deﬁ  ne this early phase (Petersen 1995; Petersen et al 2001).
Findings regarding the prevalence of MCI are few and inconsistent, probably 
due to the use of different deﬁ  nitional criteria and different sampling and assessment 
methods (for reviews see Bischkopf et al 2002; Portet et al 2006). Population-based 
studies showed prevalence rates ranging from 3% to 19% (Frisoni et al 2001; Ritchie 
and Artero 2001; Hanninen et al 2002), with higher rates associated with increasing 
age and lower education. Discrepancies are also reﬂ  ected in studies examining con-
version rates from MCI to AD. It has been reported that approximately 2% to 25% 
of those carrying the diagnosis of MCI converted to AD per year (Bowen et al 1997; 
Kluger et al 1999; Petersen et al 1999, 2001). Using a mathematical model based on 
assumptions regarding AD prevalence rates and conversion rates from MCI to AD, 
Yesavage and colleagues (2002) predicted that MCI prevalence increases from 1% at 
age 60 to 42% at age 85. However, in this study, MCI was only deﬁ  ned as pre-AD. 
Inclusion of other MCI subtypes will of course inﬂ  ate these ﬁ  gures.
The ongoing growth of the elderly population increases the need to further our 
understanding about MCI as a prodrome to dementia, about its identiﬁ  cation and neu-
ropathologic correlates, and pharmacological and behavioral treatment approaches. 
This review attempts to synthesize the current research in the area of MCI and its Clinical Interventions in Aging 2008:3(3) 414
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implications on conceptual, methodological, social, and 
ethical aspects which have attracted less attention. It is not 
intended to be an exhaustive nor systematic review, but to 
discuss and focus on several important nonmedical issues 
associated with this state.
Conceptual issues
The ﬁ  rst step towards the development of a coherent body 
of research is to have a clear and explicit deﬁ  nition at the 
construct level, that is, to delineate the concept under study 
(Cohen 1991). In this section, we will therefore summarize 
and discuss the conceptual development and controversies 
related to the term MCI.
Multiple terms have been used to describe subclinical 
cognitive deﬁ  cits (for a more comprehensive description 
of the terminology developments see Petersen (2004) and 
Dierckx et al (2007)). These included “benign senescent 
forgetfulness” (BSF), proposed in the early 1960s by Kral 
(1962) and “age-associated memory impairment” (AAMI), 
introduced and adopted by the National Institute of Mental 
Health in the late 1980s (Crook and Larrabee 1991). Despite 
their contribution as heuristics for the development of 
research, these terms were limited by the lack of precision of 
the concepts, and both were regarded as variants of normal 
aging. Aging-associated cognitive decline (AACD) was sug-
gested to overcome these criticisms (Levy 1994).
The prevailing term today to describe the transitional 
phase between normal aging and dementia is MCI. Initially, 
the diagnostic criteria for MCI included: 1) memory com-
plaints, preferably corroborated by an informant; 2) objec-
tive memory impairment, beyond that expected for age and 
education; 3) normal general cognitive functioning; 4) intact 
activities of daily living; and 5) not being demented (Petersen 
and Morris 2003). Lately, the concept of MCI has been 
expanded to address observed clinical heterogeneity, and 
two subtypes were included: amnestic (consisting memory 
impairment) and nonamnestic (impairment in other cognitive 
domains) (Winblad et al 2004).
In spite of the considerable reﬁ  nement in the deﬁ  nition 
of MCI, several clariﬁ  cations might still be required in 
order for MCI to be considered as a helpful concept. For 
example, although the deﬁ  nition of AD includes the exclu-
sion of other central nervous system conditions that could 
cause cognitive decline, such as Parkinson’s disease and 
strokes, and the exclusion of systemic conditions such as 
hypothyroidism or vitamin B12 deﬁ  ciency (as though these 
could not coexist with AD), the deﬁ  nition of MCI requires 
the exclusion of dementia only. On a syndromic level, this 
is quite appropriate, since mild cognitive decline may herald 
other types of dementia and can occur in other brain diseases, 
such as multiple sclerosis. While this at the same time marks 
the limitations of the concept as a transitional state to AD 
in aging people, it should be a sign demanding explanation 
and possibly treatment.
Moreover, there is a need to limit the deﬁ  nition of MCI to 
newly developed cognitive decline, in order to exclude cases 
who might present cognitive impediments as a result of long 
term limitations, such as persons suffering from mental retar-
dation or brain trauma. This obvious limitation is not included 
in the existing deﬁ  nitions (Petersen et al 2001; Ritchie and 
Artero 2001), but mentioned later (Portet et al 2006).
The therapeutic implications of the diagnosis of MCI 
should be clear. Attempts to treat MCI as if it were incipient 
AD, using cholinesterase inhibitors, have failed. This may 
not be surprising if the endpoint was conversion to dementia, 
since the drugs available for AD merely provide symptomatic 
beneﬁ  t and do not slow disease progression. This situation 
will hopefully change once disease-modifying therapies are 
developed. However, at present, the heterogeneous nature 
of MCI should alert the clinician in each individual case 
to attempt to reach an etiological diagnosis that may direct 
therapy (eg, for depression, vascular brain disease or vitamin 
deﬁ  ciency).
Finally, it should be stressed that MCI nosologically is 
not a unique entity: it is rather heterogeneous. It may carry a 
grave prognosis, such as becoming demented within a short 
time (2%–25% annual conversion to AD), although many 
people remain stable, deteriorate slowly, and a surprising 
number even improve spontaneously (Bowen et al 1997; 
Kluger et al 1999; Petersen et al 1999; Ganguli et al 2004). 
This again points to the difﬁ  culty of using a complaint, or a 
symptom, as the main diagnostic tool. The attempt to deﬁ  ne 
those people who are at a prodromal stage to the development 
of dementia, will probably only be ﬁ  rmly established once 
biological markers of incipient dementia are identiﬁ  ed. It is 
now accepted that signiﬁ  cant AD changes can occur in the 
human brain prior to the emergence of symptoms (Price and 
Morris 1999). If this is the case, it is likely that biological 
markers could indeed be found.
Although it is claimed that apolipoprotein E4, neuro-
imaging, and neuropsychological testing may give some 
guidance as to who may progress more rapidly, there are no 
good indicators as to who will or will not convert, and this of 
course has important implications on whether the diagnosis 
should be revealed to the subject or not (see Ethical issues 
below).Thus, viewing MCI as “very mild AD” is erroneous Clinical Interventions in Aging 2008:3(3) 415
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and counterproductive (Morris 2006). If we know it to be 
AD, this is the name that should be used. It seems that the 
prevalent use of the term is employed both to cover our 
ignorance at not being able to secure a deﬁ  nite diagnosis, 
as well as sometimes to provide patients with an easier-to-
swallow pill.
The emergence of the concept of MCI at this stage is 
not coincidental. Its creation and popularity are related 
to obvious industrial and economic interests. In the past, 
attempts to develop drugs for subjects with AAMI met stiff 
resistance from authorities such as the FDA, primarily based 
on the assumption that drugs should only be used to combat 
disease, whereas conditions such as “normal” aging should 
not be a target for drug manipulation. The term MCI, used to 
indicate a transitional state between normal aging and AD, 
serves the political purpose of deﬁ  ning it as an abnormal 
state and therefore a legitimate target for drug manipula-
tion, carrying important economic implications. Until these 
discrepancies are solved, debates about the usefulness of the 
concept will continue (Palmer and Winblad 2007; Petersen 
2007; Whitehouse 2007).
Assessment issues
Assessment issues regarding MCI are still in developmen-
tal stages (for a recent review on this topic see Gauthier 
et al 2006). The latest extended deﬁ  nition of MCI calls for 
assessing ﬁ  rst the person’s cognition function. This can 
usually be accomplished by taking a clinical history and 
performing a mental status exam, possibly complemented 
by the use of neuropsychological testing, including memory 
tests and possibly tests for other cognitive domains. Finally, 
the etiology of the symptoms should be elucidated based 
on clinical evaluation, laboratory testing and neuroimag-
ing studies.
Many of these stages are still subject to debate. For 
example, there are no details or guidance regarding the 
memory instrument to be used. Memory instruments vary 
in their psychometric characteristics, such as sensitivity 
and speciﬁ  city (Werner 2001), and so persons meeting the 
deﬁ  nition of MCI by one instrument might be excluded if 
another is used. Also, the degree of dysfunction in memory 
test has not been deﬁ  ned. The 1.5 standard deviation value 
frequently given refers to the group value and should not be 
applied to an individual. In principle, any value is not appro-
priate, since AD develops insidiously and any chosen value is 
arbitrary. Moreover, it does not refer to the premorbid level 
of the subject. Regarding nonamnestic MCI, the confusion 
seems to be even larger, since no suggestions are provided 
as to which cognitive domains should be explored and how 
these should be tested.
Regarding neuropsychological tests, these should 
complement and not replace clinical assessment and should 
be brief in order to be of practical use and also in order to 
avoid fatigue in the elderly person. Because different domains 
might ﬁ  rst be affected in a population with incipient demen-
tia, a test which examines more than a single functional 
domain might be needed. One possible solution is to use 
self-administered, computerized neuropsychological tests 
(Aharonson et al 2004).
Finally, neuroimaging (such as computerized tomography 
and magnetic resonance imaging) and biomarkers (such as 
high cerebrospinal ﬂ  uid [CSF] tau values, low CSF beta 
amyloid (Hansson et al 2006), and the presence of apoli-
poprotein E gene 4 allele (Treves et al 1996; Petersen et al 
2001)) are helpful tools in the diagnosis of MCI (Petersen 
et al 2001). However, these markers are expensive and time 
consuming, and presumably only relevant to MCI in the 
context of incipient AD.
In summary, the last years were characterized by con-
siderable advances in the conceptualization and assessment 
aspects of cognitive decline in old age (Winblad et al 2004). 
These advances have, however, elicited ethical and social 
issues. Their importance will be discussed in the following 
sections.
Ethical issues
Ethical issues related to dementia have received increased 
attention during the last decade (Post and Whitehouse 1995; 
Post 2000). As knowledge around MCI expands, researchers, 
clinicians and the lay public will be confronted with ethical 
issues in this area as well. In this section, we will discuss 
several of these issues.
Disclosing the diagnosis
One of the main ethical issues concerns the disclosure of 
the diagnosis of a disease to the person and his/her family. 
This issue involves the dilemma between the patient’s right 
to know and withholding the information in order to avoid 
distress and harm (Baldwin et al 2003).
Although empirical data in the area of MCI are very lim-
ited, ﬁ  ndings for AD may trigger further research and open 
the debate about the dilemmas involved in informing persons 
about a diagnosis of MCI. The beneﬁ  ts about revealing a 
diagnosis of AD include allowing patients to be involved in 
decision-making processes regarding their future, respecting 
their autonomy, and providing relief by putting a “label” to Clinical Interventions in Aging 2008:3(3) 416
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their symptoms (Maguire 2002; Pinner and Bouman, 2002). 
Pitfalls for disclosing the diagnosis to patients include con-
cerns about precipitating fear and distress, reducing hope and 
positive thinking, and inducing depression and even suicidal 
ideation (Johnson et al 2000; Pucci et al 2003). It should be 
stressed that these hypothetical negative consequences were 
rarely supported by empirical data in AD (Heal and Husband, 
1998; Jha et al 2001; Holroyd et al 2002; Husband 2002; 
Vernooij-Dassen et al 2003), and are still awaiting empirical 
conﬁ  rmation in MCI. The situation in MCI is more complex 
because MCI is not identical to incipient dementia and not 
all cases necessarily progress (for a discussion on “reversible 
MCI”, see de Rotou et al 2005). Thus, uncertainty concerning 
the prognosis in MCI is more prolonged than in AD or other 
dementing disorders.
It is important to stress again that not all cases diagnosed 
as MCI will progress (Brooks 2007), and this should be 
conveyed clearly to the subject, who must not be left with 
the impression that MCI is identical with incipient dementia. 
This point is particularly valid in sites where there are fewer 
experts who are knowledgeable about the complexities of the 
diagnosis of MCI, notably in Eastern Europe and Asia.
In sum, there is a need to accumulate more data to assess 
whether the disclosure of a diagnosis of MCI will be accom-
panied by increased fears, concerns, and feelings of helpless-
ness, or whether it would help the subject and his/her family 
to prepare for the future. Other questions awaiting further 
research include the clinical practice to be used for disclosing 
the diagnosis, whether the label of MCI should be used or 
not, whether the diagnosis of MCI should be accompanied 
by driving restrictions, etc.
Stigmatization
Another aspect we should consider when weighing the 
beneﬁ  ts and problems of disclosing the diagnosis of MCI 
is whether this will affect the way the subject is viewed by 
others—in other words, whether a diagnosis of MCI would 
be accompanied by stigmatization or not.
While it is well known that stigmatization affects the 
lives of demented persons and their caregivers (Benbow and 
Reynolds 2000; Jolley and Benbow 2000; Vernooij-Dassen 
et al 2003), empirical research related to MCI is still scant.
A public opinion poll conducted on behalf of the 
Alzheimer’s Society of Canada among adult Canadians 
(Alzheimer’s Society of Canada 2003), showed that as many 
as 81% of the 1,000 participants felt they would be looked 
upon or treated differently if others knew they were diagnosed 
with AD. Findings of a survey of over 1,700 participants, 
aimed at assessing British adults’ opinion about those with 
seven mental illnesses (severe depression, panic attacks, 
schizophrenia, eating disorders, alcohol addiction, drug 
addiction, and dementia), found that the highest percent-
age of participants perceiving that the patient would feel 
that he or she was being looked upon differently related to 
dementia (61%) (Crisp et al 2000). It should be noted that 
while neither one of these surveys provided information 
about whether “being looked upon differently” related to 
positive or negative reactions, two recent studies found that 
lay persons relate to a person with AD with more positive 
than negative emotions (Wadley and Haley 2002; Werner 
and Davidson 2004).
The question facing us today is whether similar ﬁ  nd-
ings will be associated with a diagnosis of MCI. Would a 
person who has been given a diagnosis of MCI be “looked 
upon differently”? Would this label affect the diagnosed 
person’s social functioning? Quality of life? Would his/her 
relatives be affected as well by the diagnosis? If the label 
of MCI becomes associated more with disease than with 
normal aging (Whitehouse and Juengst 2005), stigmatic 
views might prevent persons with MCI and their family 
members to seek appropriate help in an effort to conceal 
the problem. These issues are especially important since 
persons with MCI might still be actively involved in work 
and family roles.
Social issues
Despite the ongoing conceptual debate regarding MCI, the 
increase of the aging population together with the advances 
in the diagnosis of early dementia or MCI, will be accom-
panied also by social challenges, such as cost-related issues, 
and the development of appropriate services for persons 
with a diagnosis of MCI and their relatives. Although some 
of the services suggested in this section are associated with 
increased resources, it is our belief that the body of knowl-
edge about MCI requires society to adapt existing services 
and/or develop new ones for this population.
Economic issues
Numerous studies in different countries have shown that the 
economic costs associated with the formal and informal care 
of AD are very high (Gray and Fenn 1993; Hux et al 1998; 
Coon and Edgerly 1999; Taylor and Sloan 2000; Beeri et al 
2002), and that early diagnosis of the disease is associated 
with considerable reductions in costs (Taylor and Sloan 
2000; Leifer 2003), especially in the costs of long term care 
services. However, as stated by Wimo and Winblad (2003) Clinical Interventions in Aging 2008:3(3) 417
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it is not known to what extent results regarding AD can be 
extrapolated to MCI.
With the developments in the diagnosis and treatment 
of MCI, increased efforts should be invested to predict 
the short- and long-term costs speciﬁ  cally associated with 
this diagnosis. Comas-Herrera and colleagues (2003), in a 
study aimed at making projections regarding the economic 
demands associated with cognitive impairment, found that 
an improved diagnosis of dementia and MCI, and a decline 
of 1% per year in the prevalence of moderate to severe 
cognitive impairment, will be accompanied by a decline on 
the percentage of expenses for long term care services from 
the Gross Domestic Product for the next 30 years. What 
this report fails to consider is the fact that reductions in 
long term care costs might be accompanied by an increase 
in community-based services aimed at helping persons with 
MCI and their relatives. Efforts should then be invested not 
only in the development of social services answering to the 
needs of those diagnosed with MCI, but also in prevention 
programs against the development of MCI (ie, primary pre-
vention; Wimo and Winblad 2003), or its transformation to 
AD (ie, secondary prevention).
Development of services for those 
with a diagnosis of MCI
Advances in the diagnosis of MCI have to be accompanied 
by a reorganization of existing services, and by the develop-
ment of new services for subjects with MCI and their rela-
tives. Some of these efforts might concentrate on expanding 
existing programs for elderly persons in the early stages of 
dementia to those diagnosed with MCI. Two such services 
are support groups for persons in the ﬁ  rst stages of dementia 
and memory training programs.
In the last few years, we have witnessed an increase in 
the development of services for persons in the initial stages 
of dementia. The use of support groups for elderly persons 
in the ﬁ  rst stages of AD started to develop in the middle to 
late 90’s (Yale 1995; Goldsilver and Grunier 2001). Sev-
eral evaluation studies showed them to be beneﬁ  cial to the 
participants, who expressed satisfaction especially with the 
information and knowledge they received regarding the dis-
ease and its treatment (Chung 2001; Goldsilver and Grunier 
2001; Werner 2003). Based on these ﬁ  ndings, the use of 
support groups for persons with MCI should be considered. 
Such programs are also useful against the effects of stigma-
tization on the individual, and may include the provision 
of information regarding MCI and its progression, as well 
as information regarding life style changes associated with 
secondary prevention in persons with MCI, such as physical 
activity and nutritional aspects (Rosenberg et al 2006; van 
Uffelen et al 2007).
Another service to consider is the expansion of memory 
training or memory enhancement programs. These are aimed 
at maintaining or improving memory skills in healthy elderly 
persons (Scogin and Bienias 1988; Lachman et al 1992; 
Andrews et al 1996) by relying on a variety of cognitive 
techniques, such as imagery, as well as on noncognitive 
techniques such as relaxation. Although evidence about 
their effectiveness is inconsistent (McKitrick et al 1992; 
Sandman 1993; Floyd and Scogin 1997; Werner 2000), 
recent studies showed that cognitive rehabilitation might be 
a useful program in persons with MCI (Talassi et al 2007). 
Therefore, efforts to develop memory enhancement programs 
for persons with MCI should be expanded and their results 
evaluated. Such programs should be accompanied by the dif-
fusion of knowledge about MCI, its prognosis and treatment, 
as well as the provision of information about the available 
services in the community.
Future interventions should concentrate also on develop-
ing education strategies for healthcare providers (especially 
for primary care providers such as family physicians, nurses, 
and social workers), as well as for the lay public. Recent 
studies assessing the lay public’s knowledge about AD 
found that levels of knowledge are negatively associated to 
age (Kahana et al 2003; Werner 2004, 2005). Thus, health 
education programs should be aimed speciﬁ  cally to the needs 
of the older section of the population. Given the relatively 
low computer literacy of this group, education programs 
should try to reach elderly persons through more conventional 
sources, especially care providers, and materials published in 
the general media, such as television and newspapers.
Development of social programs and 
initiatives for the prevention of MCI
Marked advances have been made lately in the identiﬁ  cation 
of risk factors for the development of AD. Attention to clini-
cal risk factors, such as hypertension and hyperlipidemia, 
have been shown to reduce or delay the incidence of demen-
tia (Korczyn 2002). Social factors, such as high education, 
increased psychosocial networking, and participation in 
leisure activities, have also been associated with a reduced 
risk of dementia (Gwyther 1997; Kahana et al 2003; Seidler 
et al 2003; Verghese et al 2003). It is unknown as yet to what 
extent attention to these factors could delay the conversion 
of MCI to AD. Nevertheless, given these advances, it is not 
too soon to implement medical and social interventions for Clinical Interventions in Aging 2008:3(3) 418
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the primary prevention of MCI. These might include the 
allocation of resources for the development and conduction 
of information campaigns stressing the beneﬁ  ts of partici-
pation in appropriate health behaviors as well as in leisure 
activities. Additionally, efforts should be invested in training 
professionals not only in the identiﬁ  cation of MCI, but also 
in providing adequate information and guidelines regarding 
its prevention and consequences. Individuals diagnosed as 
MCI could beneﬁ  t from frank discussion of the implications 
of the diagnosis. Particularly in those suspected of harboring 
incipient dementia, discussion of writing a will and instruc-
tions about participation in research on demented individuals, 
prolongation of life and consent to autopsy are some obvious 
steps that should preferably be done prior to the development 
of frank dementia.
Development of services for family 
members of persons with MCI
Although still limited, studies regarding burden among 
spouses of persons with MCI found elevated levels of care 
giving burden (Garand et al 2005). In consideration of these 
ﬁ  ndings, efforts should be invested in developing and assess-
ing the effectiveness of interventions geared towards the 
speciﬁ  c needs of this population.
Concluding comments
In recent years, we witnessed a growing interest in the topic of 
MCI. The aim of the present paper was to examine critically 
some conceptualization, assessment, ethical, and social issues 
involved, which might suggest the direction and emphasis 
of future research.
Although research on MCI is beyond its early stages, 
researchers and clinicians continue debating the usefulness 
of the concept. Consequently, academically led discussion 
groups should continue to meet and discuss the concept. 
Furthermore, there is need to expand the areas of research 
to concentrate not only on the clinical aspects of the concept 
but also on its ethical and societal aspects.
Overall, there is need to recognize that MCI is not a 
disease, but rather a syndrome. Some subjects may actually 
suffer from depression; others from anxiety, still others from 
vascular brain disease and many have prodromal AD. As 
a result of this, increased efforts should be made to iden-
tify the etiology of the disorder in each individual. Until a 
clearer understanding is achieved, rational therapy cannot 
be provided.
Future efforts should also be invested in the develop-
ment of hypotheses examining predictors of MCI, as well 
as outcomes. Predictor variables may include biological and 
genetic factors, but also social and cultural ones. Outcome 
variables may include personal adjustment and mental health 
variables, such as depression, life satisfaction and well-being, 
as well as society-level outcome variables, such as cost and 
policy issues.
Special attention should be paid to the perspectives and 
insights of the persons diagnosed with MCI (Werner 2004). 
How does a diagnosis of MCI affect their self-esteem, anxi-
eties and concerns? What is the effect on their relationships 
with family members and formal caregivers, if any (Joosten-
Wein Banningh et al 2007)? How is their independence and 
functioning in social roles (such as worker, employer, spouse, 
parent, or grandparent) impacted?
Methodologically, there is a need to expand the research 
on the development and validation of reliable instruments 
for the assessment of MCI and particularly predicting future 
changes. This should be accompanied by training health-
care providers in the administration of these instruments, 
in order to attain a reliable diagnosis in the clinical setting, 
and not only in research settings. In addition, longitudinal 
studies aimed at examining changes along time should be 
encouraged.
Finally, educational efforts should be expanded and 
assessed systematically. These include educating lay persons 
regarding MCI, and the importance of an early diagnosis of 
memory and other cognitive problems, as well as educating 
health care professionals.
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